Alternatives to Emmecell

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing ultrasound-mediated nonviral genetic medicines.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing novel male contraceptives.

Developing a new histotripsy therapeutic platform for cancer treatment.

Develops and distributes bioreactor technology for stem cell cultivation.

Elevating uterine health through innovative biomaterial therapies.

Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

A global leader in clinical pharmacology and bioanalytical sciences.

Developing novel immunotherapies and diagnostics for cancer.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Developing gene editing therapies to lower cholesterol.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A full-stack spatial biology company.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing first-in-class oral therapy for BK polyomavirus infections.

Developing epigenetic reprogramming drugs for age restoration.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Advancing targeted alpha therapies.

A biopharmaceutical company focused on drug discovery and development.

Platform designed to cut cell and gene therapy production costs.

AI-enabled technology for cell biology research and biopharma development.

Developing and manufacturing laminin-based cell culture substrates for advanced cell therapies and drug discovery.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.